FDA announces reorganization and CTAGTAC votes on Duchenne muscular dystrophy and melanoma therapies

The FDA disclosed a major internal reorganization aimed at streamlining its operations and improving efficiency across its divisions.

The agency’s Cellular, Tissue, and Gene Therapies Advisory Committee (CTAGTAC) convened to consider recommendations for therapies targeting Duchenne muscular dystrophy and melanoma, casting votes on whether to advance these candidates.

These steps signal the FDA’s focus on accelerating review processes while maintaining rigorous evaluation of emerging treatments, a development of interest to pharma companies and investors monitoring regulatory pathways.